Press Releases
GT Biopharma to Participate in the 10th Anniversary of the Innate Killer Summit
GT Biopharma Announces Exercise of Warrants
GT Biopharma Announces Request for Withdrawal of Form S-1 Registration Statement
GT Biopharma Announces First Patient Dosed in Phase 1 Trial of GTB-3650, Second-Generation TriKE for the Treatment of Hematologic Malignancies
GT Biopharma Reports Third Quarter 2024 Financial Results
GT Biopharma to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference
GT Biopharma to Host Virtual KOL Event Showcasing its NK Cell Engager Pipeline and Broad Indication Potential on October 10, 2024
GT Biopharma Reports Second Quarter 2024 Financial Results and Provides Corporate Update
GT Biopharma Announces FDA Clearance of Investigational New Drug (IND) Application for GTB-3650, an NK Cell Engager for Treatment of CD33+ Leukemia
